公开(公告)号：US20230181599A1

公开(公告)日：2023-06-15

申请号：US17923532

申请日：2021-05-06

申请人： Shenzhen Evergreen Therapeutics Co., Ltd

发明人： Xin Du ,  Tao Tom Du ,  Weiwei Hua

IPC分类号： A61K31/57 ,  A61K45/06 ,  A61P11/00 ,  A61K9/48

CPC分类号： A61K31/57 ,  A61K45/06 ,  A61P11/00 ,  A61K9/4825

摘要： Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.

公开(公告)号：US11666547B2

公开(公告)日：2023-06-06

申请号：US16915746

申请日：2020-06-29

申请人： NORTHWESTERN UNIVERSITY

发明人： Marco Martina ,  Herbert Y. Meltzer

IPC分类号： A61K31/196 ,  A61K31/4365 ,  A61P25/18 ,  A61P25/24 ,  A61K31/57 ,  A61K45/06

CPC分类号： A61K31/196 ,  A61K31/4365 ,  A61K31/57 ,  A61P25/18 ,  A61P25/24 ,  A61K45/06

摘要： Disclosed are methods for treating a psychiatric disease or disorder and/or symptoms thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of an antagonist of the Na+-K+-2Cl— cation-chloride cotransporter isoform 1 (NKCC1) for treating the psychiatric disorder and/or the symptoms thereof in the subject. The methods further may include administering to the subject a dopamine D1 agonist and/or a GABAA agonist, optionally at a subeffective dose, where co-administering the antagonist of NKCC1 improves the efficacy of the dopamine D1 agonist and/or the GABAA agonist, optionally at the subeffective dose, for treating the psychiatric disease or disorder and/or symptoms thereof.

公开(公告)号：US20230165788A1

公开(公告)日：2023-06-01

申请号：US17995542

申请日：2021-04-07

申请人： Research Triangle Institute

发明人： Leah Marie JOHNSON ,  Linying Alice LI ,  Sai Archana KROVI ,  Ariane VAN DER STRATEN

IPC分类号： A61K9/00 ,  A61K31/7076 ,  A61K31/675 ,  A61K45/06 ,  A61K47/44 ,  A61K47/34 ,  A61P31/18 ,  A61K31/575 ,  A61K31/57 ,  A61P15/18

CPC分类号： A61K9/0024 ,  A61K31/57 ,  A61K31/575 ,  A61K31/675 ,  A61K31/7076 ,  A61K45/06 ,  A61K47/34 ,  A61K47/44 ,  A61P15/18 ,  A61P31/18

摘要： A reservoir device comprising an active agent formulation contained within a reservoir is described. The active agent formulation comprises more than one active agent. The reservoir is defined by a biodegradable, permeable polymer membrane. The membrane allows for diffusion of the more than one active agent of the formulation there through when positioned subcutaneously in a body of a subject.

公开(公告)号：US11628175B2

公开(公告)日：2023-04-18

申请号：US17184181

申请日：2021-02-24

申请人： CHIESI FARMACEUTICI S.P.A.

发明人： Claudio Cafiero ,  Leonardo Ortenzi ,  Francesca Schiaretti

IPC分类号： A61K31/57 ,  A61K9/00 ,  A61K9/14 ,  A61K9/16 ,  A61K31/00 ,  A61K31/167 ,  A61K31/194 ,  A61K31/40 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26

摘要： Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

公开(公告)号：US20230092955A1

公开(公告)日：2023-03-23

申请号：US17948271

申请日：2022-09-20

申请人： Celanese EVA Performance Polymers LLC

发明人： Vijay Gyanani ,  Jeffrey Haley ,  Keith Henry ,  Kevin Welsh

IPC分类号： A61M5/142 ,  A61P15/18 ,  A61F6/14 ,  A61K31/566 ,  A61K31/57

摘要： An implantable and refillable device for delivering a contraceptive agent is provided. The device comprises a reservoir within which the contraceptive agent is capable of being retained, wherein the reservoir defines a first surface and a second surface opposing the first surface. A release structure comprising a hydrophobic polymer surrounds at least a portion of the reservoir. The release structure is in communication with the reservoir such that the contraceptive agent can pass from the reservoir through the release structure. A septum is positioned adjacent to the first surface of the reservoir and a backing layer is positioned adjacent to the second surface of the reservoir.

公开(公告)号：US20230091716A1

公开(公告)日：2023-03-23

申请号：US17904035

申请日：2021-02-11

申请人： Glia, LLC

发明人： Zhonghui Katie LUO ,  Kenneth I. SAWYER ,  Wei-Wei CHANG

IPC分类号： A61K31/57 ,  A61K9/00 ,  A61K31/573 ,  A61K31/569 ,  A61K9/06 ,  A61P27/02 ,  A61P37/06 ,  A61F9/00

摘要： The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery.

公开(公告)号：US20230070977A1

公开(公告)日：2023-03-09

申请号：US17483199

申请日：2021-09-23

申请人： Millicent Pharma Limited

发明人： Roger M. Boissonneault ,  Ryan Loughlin

IPC分类号： A61K31/565 ,  A61K31/57

摘要： A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.

公开(公告)号：US11596601B2

公开(公告)日：2023-03-07

申请号：US16663759

申请日：2019-10-25

申请人： Viramal Ltd.

发明人： William Bologna ,  François Boutignon ,  Lea Louvel ,  Finn Larsen ,  Simona Fiore ,  Oliver Bates

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/57 ,  A61K47/06 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38

摘要： A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises a vehicle with a gel-forming agent and a bioadhesive agent; and a therapeutic agent dispersed or suspended in the vehicle.

公开(公告)号：US20230055912A1

公开(公告)日：2023-02-23

申请号：US17816084

申请日：2022-07-29

申请人： Regeneron Pharmaceuticals, Inc. ,  The Royal Institution for the Advancement of Learning / McGill University

发明人： Jonas Bovijn ,  Okukayode Sosina ,  Sirui Zhou ,  Luca Andrea Lotta ,  Aris Baras ,  Brent Richards

IPC分类号： C12N15/113 ,  C12Q1/6883 ,  A61K31/663 ,  A61K31/675 ,  A61K38/23 ,  A61K38/29 ,  C07K16/28 ,  A61K31/565 ,  A61K31/57 ,  A61K31/4535

摘要： The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

公开(公告)号：US20230036801A1

公开(公告)日：2023-02-02

申请号：US17385057

申请日：2021-07-26

申请人： Navad Life Sciences Pte

发明人： Michael Oettel ,  Hermann Osterwald ,  Prithi S. Kochhar

IPC分类号： A61K31/57 ,  A61K9/00 ,  A61P15/18

摘要： A method for providing progestogen only contraception.